Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics

Global Cord Blood and Tissue Banking Industry Report 2022: More than 70% of the Global Cord Blood Market is controlled by the World’s 12 Largest Cord Blood Banking Operators -

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 9, 2023 GMT

DUBLIN--(BUSINESS WIRE)--Jan 9, 2023--

The “Global Cord Blood and Tissue Banking Industry Report 2022” report has been added to’s offering.

Today, more than 70% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of merger and acquisition (M&A) activity in recent years, with market leaders gaining market share at the expense of smaller competitors and investors vying for buy-in opportunities.

Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex-vivo cord blood expansion are advancing at a brisk pace.

Substantial cord blood industry consolidation has happened in recent years and investor appetite for cord blood banks has never been stronger. This is because cord blood banks produce stable subscription revenue from long-term storage contracts. At a fundamental level, cord blood banks are both a real estate play (cryogenic storage facilities) and a regenerative medicine (RM) play.


In addition to an aggressive M&A environment, a growing number of cord blood banks have been venturing into new types of stem cell storage, reproductive services, and related cell therapy applications. Specifically, cord blood, cord tissue, placental tissue, and dental pulp have demonstrated intriguing therapeutic promise, causing storage services for these biomaterials to proliferate.

Cord blood has the potential to be an important source of therapeutic cells for a growing range of regenerative medicine applications. According to, there are over 1,300 clinical trials evaluating the use of cord blood stem and progenitor cells.

These studies use unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). These studies are targeting clinical indications that range from pulmonary diseases to infertility to orthopedic conditions, but the most common area of research is neurologic conditions - such as cerebral palsy, autism, stroke, and hypoxic-ischemic encephalopathy.


Within the research realm, cord blood products (fresh and cryopreserved) are being offered by a diverse range of major market leaders, including Lonza, STEMCELL Technologies, AllCells, and dozens of others. Within the therapeutic realm, a growing number of companies are exploring the development and commercialization of perinatal products across a diverse range of applications.

The report provides the following details:

  • Number of cord blood units cryopreserved in public and private cord blood banks globally
  • Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells
  • Utilization of cord blood cells in clinical trials for developing regenerative medicines
  • Emerging technologies to influence financial sustainability of public cord blood banks
  • The future scope for companion products from cord blood
  • The changing landscape of cord blood cell banking market
  • Extension of services by cord blood banks
  • Types of cord blood banks
  • Economic model of public cord blood banks
  • Cost analysis for public cord blood banks
  • Economic model of private cord blood banks
  • Cost analysis for private cord blood banks
  • Profit margins for private cord blood banks
  • Pricing for processing and storage in private banks
  • Rate per cord blood unit in the U.S. and Europe
  • Indications for the use of cord blood-derived HSCs for transplantations
  • Diseases targeted by cord blood-derived MSCs in regenerative medicine
  • Cord blood processing technologies
  • Number of clinical trials, number of published scientific papers and NIH funding for cord blood research
  • Transplantation data from different cord blood registries


Key questions answered within the report are:

  • What are the strategies being considered to improve the financial stability of public cord blood banks?
  • What are the companion products proposed to be developed from cord blood?
  • How much is spent to process and store a unit of cord blood?
  • How much does a unit of cryopreserved cord blood unit fetch on release?
  • Why do most public cord blood banks incur a loss?
  • What is the net profit margin for a private cord blood bank?
  • What are the prices for processing and storage of cord blood in private cord blood banks?
  • What are the rates per cord blood units in the U.S. and Europe?
  • What are the revenues from cord blood sales for major cord blood banks?
  • Which are the different accreditation systems for cord blood banks?
  • What are the comparative merits of the various cord blood processing technologies?
  • What is to be done to increase the rate of utilization of cord blood cells in transplantations?
  • Which TNC counts are preferred for transplantation?
  • What is the number of registered clinical trials using cord blood and cord tissue?
  • How many clinical trials are studying the ex vivo expansion of cord blood?
  • How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
  • What is the share of cord blood transplants compared to bone marrow and peripheral blood transplants, respectively?
  • What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
  • Which are the top ten countries for donating cord blood?
  • What are the diseases targeted by cord blood and tissue derived MSCs within clinical trials?


Company Profiles


  • AXP Processing System
  • AllCells
  • AlphaCord LLC
  • Americord Registry, Inc
  • Be The Match
  • BioArchive System
  • BioEden Group, Inc
  • Biocell Center Corporation
  • Biovault Family
  • Bone Marrow
  • Cell Care
  • Cell-Save
  • Cells Life Group, LLP
  • Cellular Therapy
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • CordVida
  • Cordlife Group, Ltd
  • Core Biobank
  • Crioestaminal
  • Cryo-Cell International, Inc
  • CryoHoldco
  • Cryoviva Biotech Pvt Ltd
  • FamiCord Group
  • GeneCell International
  • Global Collaboration
  • Global Cord Blood Corporation (GCBC)
  • HealthBaby Hong Kong
  • Insception Lifebank
  • Leukopak
  • LifeCell International Pvt Ltd
  • LifebankUSA
  • MVE Liquid Nitrogen System
  • Maze Cord Blood Laboratories
  • MiracleCord, Inc
  • Mobilized Leukopak
  • New England Cord Blood Bank, Inc
  • New York Cord Blood Center (NYBC)
  • NextGen Collection System
  • PacifiCord
  • Placental Banking
  • ReeLabs Pvt Ltd
  • ScellCare
  • Smart Cells International, Ltd
  • StemCyte, Inc
  • ToothScell
  • TotiCyte Technology
  • Transcell Biolife
  • ViaCord
  • Vita AG
  • Whole Blood
  • World Marrow Donor Association (WMDA)
  • Worldwide Network for Blood & Marrow Transplantation (WBMT)

For more information about this report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2023.

PUB: 01/09/2023 10:41 AM/DISC: 01/09/2023 10:41 AM